Integrated network pharmacology and metabolomics to reveal the mechanism of QiShenYiQi Dripping Pills against cardiac structural and functional abnormalities

Zhang, Jun; Yang, Zunyuan; Xue, Jian; Li, Xinxin; Wang, Xiangyang; Hua, Rong; Liang, Yinan; Wang, Jia; Ma, Xiaojing

doi:10.3389/fphar.2022.1017433

Cited by 2 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recent technological developments in metabolomics, proteomics, genomics, and transcriptomics have provided new insights into the potential use of herbal medicines for disease treatment ( Guo et al, 2022 ). Therefore, interest is increasing regarding the therapeutic applications of traditional Chinese medicine ( Zhang et al, 2022 ; Wu et al, 2022 ; Pan et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Metabolomics-based discovery of XHP as a CYP3A4 inhibitor against pancreatic cancer

et al. 2023

View full text Add to dashboard Cite

Background: Xihuang Wan (XHW), a purgative and detoxifying agent, is commonly utilized in modern medicine as a treatment and adjuvant therapy for various malignancies, including breast cancer, liver cancer, and lung cancer. A clinical study demonstrated the potential usefulness of the combination of XHW and gemcitabine as a therapy for pancreatic cancer (PC), indicating that XHW’s broad-spectrum antitumor herbal combination could be beneficial in the treatment of PC. However, the precise therapeutic efficacy of XHW in treating pancreatic cancer remains uncertain.Aim: This study assessed the biological activity of XHW by optimizing the therapeutic concentration of XHW (Xihuang pills, XHP). We performed cell culture and developed an animal test model to determine whether XHP can inhibit pancreatic cancer (PC). We also applied the well-known widely targeted metabolomics analysis and conducted specific experiments to assess the feasibility of our method in PC therapy.Materials and Methods: We used UPLC/Q-TOF-MS to test XHP values to set up therapeutic concentrations for the in vivo test model. SW1990 pancreatic cancer cells were cultured to check the effect the anti-cancer effects of XHP by general in vitro cell analyses including CCK-8, Hoechst 33258, and flow cytometry. To develop the animal model, a solid tumor was subcutaneously formed on a mouse model of PC and assessed by immunohistochemistry and TUNEL apoptosis assay. We also applied the widely targeted metabolomics method following Western blot and RT-PCR to evaluate multiple metabolites to check the therapeutic effect of XHP in our cancer test model.Results: Quantified analysis from UPLC/Q-TOF-MS showed the presence of the following components of XHP: 11-carbonyl-β-acetyl-boswellic acid (AKBA), 11-carbonyl-β-boswellic acid (KBA), 4-methylene-2,8,8-trimethyl-2-vinyl-bicyclo [5.2.0]nonane, and (1S-endo)-2-methyl-3-methylene-2-(4-methyl-3-3-pentenyl)-bicyclo [2.2.1heptane]. The results of the cell culture experiments demonstrated that XHP suppressed the growth of SW1990 PC cells by enhancing apoptosis. The results of the animal model tests also indicated the suppression effect of XHP on tumor growth. Furthermore, the result of the widely targeted metabolomics analysis showed that the steroid hormone biosynthesis metabolic pathway was a critical factor in the anti-PC effect of XHP in the animal model. Moreover, Western blot and RT-PCR analyses revealed XHP downregulated CYP3A4 expression as an applicable targeted therapeutic approach.Conclusion: The results of this study demonstrated the potential of XHP in therapeutic applications in PC. Moreover, the widely targeted metabolomics method revealed CYP3A4 is a potential therapeutic target of XHP in PC control. These findings provide a high level of confidence that XHP significantly acts as a CYP3A4 inhibitor in anti-cancer therapeutic applications.

show abstract

Section: Introductionmentioning

confidence: 99%

Metabolomics-based discovery of XHP as a CYP3A4 inhibitor against pancreatic cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Based on modern pharmacological research, Qishen Yiqi dripping pills could adjust vitality and nourish the blood, stimulating pulse, and alleviating pain, which could be used to prevent myocardial injury and enhance the production of myocardial cells (Wu et al, 2023). Clinically, Zhang et al (2022) proved that it mainly treats symptoms of qi deficiency and blood stasis, such as chest tightness and chest pain, shortness of breath, and spontaneous sweating. Chen L, et al (2022) found that Qishen Yiqi dripping pills mainly play an auxiliary role in the treatment of patients with coronary heart disease, and Chen W, et al (2022) demonstrated that Qishen Yiqi dripping pills could be combined with Western medicine to treat diseases such as hypertension and angina.…”

Section: Introductionmentioning

confidence: 99%

Determination of Four Chemical Components in Qishen Yiqi Dripping Pills by UPLC-MS/MS Method

Lili,

Honglian,

Yanxia

et al. 2023

Pharmacognosy Magazine

View full text Add to dashboard Cite

Background In this study, the ultrahigh performance liquid chromatography mass spectrometry/mass spectrometry (UPLC-MS/MS) method was established to test the contents of protocatechuic acid (C7H6O4), salvianolic acid B (C36H30O16), rosmarinic acid (C19H14O3), and cryptotanshinone (C19H20O3) in Qishen Yiqi dripping pills. Materials and Methods Methanol was chosen as the solvent according to a certain material–liquid ratio as a solution, and the ultrasonic extraction method was used to prepare the sample solution. UPLC-MS/MS was used to complete a quantitative analysis of the contents of Qishen Yiqi dripping pills. Then, the chromatographic conditions were shown as follows. The stationary phase was Agilent ZORBAX SB-C18 (2.1 mm × 100 mm, 1.8 µm), and the mobile phase was acetonitrile–0.1% formic acid water. The column temperature was 40℃, the injection volume was 3 µL, and the flow rate was 0.2 mL⋅min–1. Finally, the determination method was built to test four chemical constituents under the multiple reaction monitoring (MRM) analysis mode. Results The retention times of protocatechuic acid, salvianolic acid B, rosmarinic acid, and cryptotanshinone were 1.26, 1.32, 1.35, and 6.76 min, respectively. In addition, the concentration ranges of four compounds were 0.25–2.0 µg⋅mL–1, 10.0–50.0 µg⋅mL–1, 5.0–50.0 µg⋅mL–1, and 1.0–10.0 µg⋅mL–1, respectively. And the standard curve showed a good linear relationship in a reasonable range ( r2 ≥ 0.9950). The average recovery rate was from 96% to 124%. The contents of protocatechuic acid, salvianolic acid B, rosmarinic acid, and cryptotanshinone were 0.12%–0.022%, 17%–8.4%, and 6.5%–8.6% in seven batches of Qishen Yiqi dripping pills, which were in the range of 23%–31%. The instrument ran stably, and the method had good accuracy and repeatability (relative standard deviation [RSD] ≤ 3%). Additionally, the test result was stable within 10 h. Conclusion The contents of the four constituents were different among different batches. The quantitative method was established to determine the four chemical components in Qishen Yiqi dripping pills, which could provide a reference for quality evaluation in vivo.

show abstract

Integrated network pharmacology and metabolomics to reveal the mechanism of QiShenYiQi Dripping Pills against cardiac structural and functional abnormalities

Cited by 2 publications

References 42 publications

Metabolomics-based discovery of XHP as a CYP3A4 inhibitor against pancreatic cancer

Metabolomics-based discovery of XHP as a CYP3A4 inhibitor against pancreatic cancer

Determination of Four Chemical Components in Qishen Yiqi Dripping Pills by UPLC-MS/MS Method

Contact Info

Product

Resources

About